Welcome to our dedicated page for Nutriband Warrant news (Ticker: NTRBW), a resource for investors and traders seeking the latest updates and insights on Nutriband Warrant stock.
Nutriband Inc. develops prescription transdermal pharmaceutical products and abuse-deterrent patch technology. Company news centers on AVERSA, its transdermal platform that incorporates aversive agents into patches intended to deter abuse, diversion, misuse and accidental exposure for drugs with abuse potential, including opioids and stimulants.
Recurring updates cover the AVERSA Fentanyl program, regulatory and intellectual-property steps, product naming and labeling work, and development relationships tied to transdermal fentanyl. Other company developments include sports tape and kinesiology products, mosquito repellent patches, distribution arrangements, subsidiary matters, shareholder meeting topics, and capital-structure updates affecting Nutriband's Nasdaq-listed common stock and warrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.